Table 3.

Demographic and clinicopathological characteristics in pancreatic cancer patients with bone metastasis.

Characteristics	Training cohort (N=167)		Validation cohort (N=68)		χ2	P
	n	%	n	%
Age	63.27±12.195		66.41±11.820			0.072*
Race					0.220	0.896
White	135	80.84	54	79.41
Black	18	10.78	7	10.29
Other	14	8.38	7	10.29
Sex					2.193	0.139
Female	74	44.31	23	33.82
Male	93	55.69	45	66.18
Histological subtype					0.998	0.802
Adenocarcinoma	108	64.67	43	63.24
Infiltrating duct carcinoma	13	7.78	8	11.76
Neuroendocrine carcinoma	21	12.57	8	11.76
Other	25	14.97	9	13.24
Grade					1.386	0.709
Well differentiated: I	20	11.98	7	10.29
Moderately differentiated: II	58	34.73	29	42.65
Poorly differentiated: III	77	46.11	27	39.71
Undifferentiated; anaplastic: IV	12	7.19	5	7.35
Primary Site					3.489	0.745
Head of pancreas	49	29.34	25	36.76
Body of pancreas	28	16.77	8	11.76
Tail of pancreas	53	31.74	18	26.47
Pancreatic duct	1	0.60	1	1.47
Other specified parts of pancreas	6	3.59	2	2.94
Overlapping lesion of pancreas	19	11.38	7	10.29
Pancreas, NOS	11	6.59	7	10.29
AJCC T stage					0.325	0.955
T1	7	4.19	3	4.41
T2	53	31.74	22	32.35
T3	65	38.92	24	35.29
T4	42	25.15	19	27.94
AJCC N stage					1.129	0.288
N0	66	39.52	32	47.06
N1	101	60.48	36	52.94
Surgery					0.625	0.429
No	152	91.02	64	94.11
Yes	15	8.98	4	5.88
Radiotherapy					0.283	0.595
No	117	70.06	50	73.53
Yes	50	29.94	18	26.47
Chemotherapy					0.157	0.692
No	71	42.51	27	39.71
Yes	96	57.49	41	60.29
Tumor size					2.186	0.335
4-38 mm	63	37.72	29	42.65
39-67 mm	74	44.31	32	47.06
68-150 mm	30	17.96	7	10.29
Brain metastasis					0.079	0.779
No	159	95.21	66	97.06
Yes	8	4.79	2	2.94
Liver metastasis					0.975	0.323
No	55	32.93	27	39.71
Yes	112	67.07	41	60.29
Lung metastasis					0.975	0.323
No	112	67.07	41	60.29
Yes	55	32.93	27	39.71

^*T test.